Literature DB >> 33422110

The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease.

Zach Dwyer1, Melany Chaiquin1, Jeffrey Landrigan1, Kiara Ayoub1, Pragya Shail1, Julianna Rocha2, Christie L Childers3, Kenneth B Storey3, Dana J Philpott2, Hongyu Sun1, Shawn Hayley4.   

Abstract

BACKGROUND: Recent work has established that Parkinson's disease (PD) patients have an altered gut microbiome, along with signs of intestinal inflammation. This could help explain the high degree of gastric disturbances in PD patients, as well as potentially be linked to the migration of peripheral inflammatory factors into the brain. To our knowledge, this is the first study to examine microbiome alteration prior to the induction of a PD murine model.
METHODS: We presently assessed whether pre-treatment with the probiotic, VSL #3, or the inflammatory inducer, dextran sodium sulphate (DSS), would influence the PD-like pathology provoked by a dual hit toxin model using lipopolysaccharide (LPS) and paraquat exposure.
RESULTS: While VSL #3 has been reported to have anti-inflammatory effects, DSS is often used as a model of colitis because of the gut inflammation and the breach of the intestinal barrier that it induces. We found that VSL#3 did not have any significant effects (beyond a blunting of LPS paraquat-induced weight loss). However, the DSS treatment caused marked changes in the gut microbiome and was also associated with augmented behavioral and inflammatory outcomes. In fact, DSS markedly increased taxa belonging to the Bacteroidaceae and Porphyromonadaceae families but reduced those from Rikencellaceae and S24-7, as well as provoking colonic pro-inflammatory cytokine expression, consistent with an inflamed gut. The DSS also increased the impact of LPS plus paraquat upon microglial morphology, along with circulating lipocalin-2 (neutrophil marker) and IL-6. Yet, neither DSS nor VSL#3 influenced the loss of substantia nigra dopamine neurons or the astrocytic and cytoskeleton remodeling protein changes that were provoked by the LPS followed by paraquat treatment.
CONCLUSIONS: These data suggest that disruption of the intestinal integrity and the associated microbiome can interact with systemic inflammatory events to promote widespread brain-gut changes that could be relevant for PD and at the very least, suggestive of novel neuro-immune communication.

Entities:  

Keywords:  Inflammatory neurodege5neration; Microbiota; Microglia; Probiotic

Year:  2021        PMID: 33422110     DOI: 10.1186/s12974-020-02062-2

Source DB:  PubMed          Journal:  J Neuroinflammation        ISSN: 1742-2094            Impact factor:   8.322


  38 in total

1.  Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.

Authors:  Erin H Norris; Kunihiro Uryu; Susan Leight; Benoit I Giasson; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 2.  Epidemiology of Parkinson's disease.

Authors:  Ole-Bjørn Tysnes; Anette Storstein
Journal:  J Neural Transm (Vienna)       Date:  2017-02-01       Impact factor: 3.575

3.  Host microbiota constantly control maturation and function of microglia in the CNS.

Authors:  Daniel Erny; Anna Lena Hrabě de Angelis; Diego Jaitin; Peter Wieghofer; Ori Staszewski; Eyal David; Hadas Keren-Shaul; Tanel Mahlakoiv; Kristin Jakobshagen; Thorsten Buch; Vera Schwierzeck; Olaf Utermöhlen; Eunyoung Chun; Wendy S Garrett; Kathy D McCoy; Andreas Diefenbach; Peter Staeheli; Bärbel Stecher; Ido Amit; Marco Prinz
Journal:  Nat Neurosci       Date:  2015-06-01       Impact factor: 24.884

4.  Vagotomy and subsequent risk of Parkinson's disease.

Authors:  Elisabeth Svensson; Erzsébet Horváth-Puhó; Reimar W Thomsen; Jens Christian Djurhuus; Lars Pedersen; Per Borghammer; Henrik Toft Sørensen
Journal:  Ann Neurol       Date:  2015-07-17       Impact factor: 10.422

5.  Lipopolysaccharide from Gut Microbiota Modulates α-Synuclein Aggregation and Alters Its Biological Function.

Authors:  Dipita Bhattacharyya; Ganesh M Mohite; Janarthanan Krishnamoorthy; Nilanjan Gayen; Surabhi Mehra; Ambuja Navalkar; Samuel A Kotler; Bhisma N Ratha; Anirban Ghosh; Rakesh Kumar; Kanchan Garai; Atin K Mandal; Samir K Maji; Anirban Bhunia
Journal:  ACS Chem Neurosci       Date:  2019-03-20       Impact factor: 4.418

6.  Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls.

Authors:  Marcus M Unger; Jörg Spiegel; Klaus-Ulrich Dillmann; David Grundmann; Hannah Philippeit; Jan Bürmann; Klaus Faßbender; Andreas Schwiertz; Karl-Herbert Schäfer
Journal:  Parkinsonism Relat Disord       Date:  2016-08-26       Impact factor: 4.891

7.  Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice.

Authors:  Yulan Xiong; Stewart Neifert; Senthilkumar S Karuppagounder; Qinfang Liu; Jeannette N Stankowski; Byoung Dae Lee; Han Seok Ko; Yunjong Lee; Jonathan C Grima; Xiaobo Mao; Haisong Jiang; Sung-Ung Kang; Deborah A Swing; Lorraine Iacovitti; Lino Tessarollo; Ted M Dawson; Valina L Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-31       Impact factor: 11.205

8.  Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study.

Authors:  Tomomi Minato; Tetsuya Maeda; Yoshiro Fujisawa; Hirokazu Tsuji; Koji Nomoto; Kinji Ohno; Masaaki Hirayama
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

Review 9.  Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention.

Authors:  Sara A Ferreira; Marina Romero-Ramos
Journal:  Front Cell Neurosci       Date:  2018-08-06       Impact factor: 5.505

Review 10.  On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease.

Authors:  Nicolas Giguère; Samuel Burke Nanni; Louis-Eric Trudeau
Journal:  Front Neurol       Date:  2018-06-19       Impact factor: 4.003

View more
  6 in total

Review 1.  Inflammatory Animal Models of Parkinson's Disease.

Authors:  Juan García-Revilla; Antonio J Herrera; Rocío M de Pablos; José Luis Venero
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  Intestinal Barrier Dysfunction in the Absence of Systemic Inflammation Fails to Exacerbate Motor Dysfunction and Brain Pathology in a Mouse Model of Parkinson's Disease.

Authors:  Aeja Jackson; Phillip A Engen; Christopher B Forsyth; Maliha Shaikh; Ankur Naqib; Sherry Wilber; Dulce M Frausto; Shohreh Raeisi; Stefan J Green; Brinda Desai Bradaric; Amanda L Persons; Robin M Voigt; Ali Keshavarzian
Journal:  Front Neurol       Date:  2022-05-18       Impact factor: 4.086

Review 3.  Intestinal Inflammation and Parkinson's Disease.

Authors:  Yu Li; Yuanyuan Chen; Lili Jiang; Jingyu Zhang; Xuhui Tong; Dapeng Chen; Weidong Le
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

4.  Impact of aging on animal models of Parkinson's disease.

Authors:  Ida Hyllen Klæstrup; Mie Kristine Just; Karina Lassen Holm; Aage Kristian Olsen Alstrup; Marina Romero-Ramos; Per Borghammer; Nathalie Van Den Berge
Journal:  Front Aging Neurosci       Date:  2022-07-28       Impact factor: 5.702

5.  Intestinal Permeability, Dysbiosis, Inflammation and Enteric Glia Cells: The Intestinal Etiology of Parkinson's Disease.

Authors:  Huijia Yang; Song Li; Weidong Le
Journal:  Aging Dis       Date:  2022-10-01       Impact factor: 9.968

Review 6.  The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.

Authors:  Emily M Klann; Upuli Dissanayake; Anjela Gurrala; Matthew Farrer; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Volker Mai; Vinata Vedam-Mai
Journal:  Front Aging Neurosci       Date:  2022-01-07       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.